The mechanisms underlying the blunted contractile response to ␤-adrenergic receptor (␤-AR) stimulation in heart failure (HF) are incompletely understood, especially with regard to ␤-AR subtype-specific regulation of L-type Ca 2ϩ channels. We evaluated the impact of HF induced by pacing tachycardia on ␤-AR regulation of L-type Ca 2ϩ channels in a canine model. To evaluate changes in the relative subcellular distribution of ␤-AR subtypes, left ventricular membranes enriched in surface sarcolemma and T-tubular sarcolemma were prepared. Radioligand binding using [ 125 I]cyanopindolol revealed that HF resulted in a comparable decrease in the density of ␤ 1 -ARs in both surface and T-tubule sarcolemma (55Ϯ4%, nϭ7, PϽ0.001; and 45Ϯ10%, nϭ7, PϽ0.01, respectively), but no significant change in ␤ 2 -AR density was observed. Whole-cell patch clamp studies demonstrated a markedly blunted increase in I Ca,L in response to saturating concentrations of the nonselective ␤-AR agonist isoproterenol (0.1 mol/L) in failing myocytes compared with control (129Ϯ20%, nϭ11, versus 332Ϯ35%, nϭ7; PϽ0.001). Experiments testing ␤ 1 -ARand ␤ 2 -AR-selective stimulation showed that the major component of the blunted response to nonselective ␤-AR stimulation in HF was caused by ␤ 2 -AR activation, resulting in a pertussis toxin-sensitive, G i -mediated inhibition of the ␤ 1 -AR-induced increase in I Ca,L . In conclusion, canine HF results in the following: (1) a uniform reduction in ␤ 1 -AR density in surface and T-tubule membrane fractions without a change in ␤ 2 -AR density; and (2) the emergence of distinct G i -coupling to ␤ 2 -ARs resulting in accentuated antagonism of ␤ 1 -AR-mediated stimulation of I Ca,L . These results have implications for optimizing the use of ␤-AR drugs in HF. (Circ Res. 2005;97:566-573.) 
T he importance of the ␤-adrenergic receptor (␤-AR) system in the pathogenesis and treatment of heart failure (HF) is well accepted. 1 For example, the extent of activation of the ␤-ARs by elevated catecholamines is inversely correlated with survival in HF. 2 Furthermore, ␤-AR blockers represent the most powerful current pharmacological therapy for HF. 1 The importance of the ␤-AR signaling system is further emphasized by recent genetic studies that have identified polymorphisms in the ␤ 2 -AR that significantly impact prognosis in patients with HF. 3 In addition, one of the hallmarks of the failing heart is a markedly blunted chronotropic and inotropic response to ␤-AR stimulation. 4, 5 Therefore, understanding the molecular mechanisms underlying altered ␤-AR regulation in HF remains a critical area of investigation.
Stimulation of ␤-AR in the heart has classically been characterized as resulting in the G s -mediated stimulation of adenylyl cyclase (AC), which leads to increased cellular cAMP activating protein kinase A (PKA). The catalytic subunit of PKA phosphorylates substrates including L-type Ca 2ϩ channels, ryanodine receptors, phospholamban, troponin I, and myosin-binding protein-C. 1 This cascade is counterbalanced by phosphodiesterases and serine-threonine phosphatases. The situation is more complex because at least 3 different ␤-AR receptor subtypes encoded by distinct genes have been identified in the heart. 6 ␤ 1 -AR and ␤ 2 -AR have been subjected to the most study and dominate the known physiological responses. In the adult human and other large mammal hearts, the ␤ 1 -AR is the predominant ␤-AR expressed (70% to 85%), and ␤ 2 -ARs make up most of the remaining 15% to 30% of ␤-ARs. 6 In addition, it has become clear that ␤-AR signaling can regulate a number of other nonclassical signaling pathways in a receptor subtype-specific fashion. 7 Prior investigations have identified multiple alterations in the classical ␤-AR signaling pathway that contribute to the impaired ␤-AR stimulation of the failing heart. Downregulation, specifically of ␤ 1 -ARs without changes in ␤ 2 -ARs, have commonly been described in HF. 1, 4 Additional studies have suggested that the remaining ␤ 1 -ARs in the failing heart are largely desensitized or uncoupled from G s , in part, because of increased activity of G-protein-coupled receptor kinases 2 and/or 5. 1, 8 An increased abundance of G ␣i has also been found in HF, which could oppose G s stimulation of AC. 9 -11 The combination of changes in the ␤-AR/cAMP/PKA cascade ultimately leads to altered regulation of contraction in the failing heart; however, the impact of these changes on the target proteins of PKA regulation may be quite distinct and are incompletely understood. In the case of the L-type Ca 2ϩ channel, blunted ␤-AR stimulation of I Ca,L in HF has been observed, 12, 13 but relatively little is known about the underlying mechanisms.
Changes in the properties of L-type Ca 2ϩ channels have also been seen in the canine tachycardia-induced cardiomyopathy model and human HF, with a decreased density of channels being detected and apparent compensatory changes in channel gating, resulting in unchanged macroscopic current density. 12, 14, 15 The alterations in L-type Ca 2ϩ channels, ␤-AR, and other proteins in HF are associated with substantial subcellular remodeling, such as a decrease in density of T-tubules. 14, 16, 17 Because localized regulation of L-type Ca 2ϩ channels by ␤-AR signaling may be critical, 18, 19 we hypothesized that alterations in the subcellular distribution of ␤-AR subtype relative to L-type Ca 2ϩ channels may contribute to impaired coupling. We secondly hypothesized that a part of the blunted ␤-AR regulation of I Ca,L is attributable to the altered regulation of the channel by ␤ 2 -ARs with increased coupling to G i . Therefore, the purposes of the present work were (1) to evaluate changes in the relative distribution of ␤ 1 -ARs and ␤ 2 -ARs in surface and T-tubular sarcolemma; (2) to determine the functional regulation of I Ca,L by ␤-AR subtype-specific stimulation; and (3) to evaluate for crosstalk between ␤ 1 -AR and ␤ 2 -AR in the regulation of L-type Ca 2ϩ channels.
Materials and Methods

Materials
All reagents were purchased from Sigma Chemical (St Louis, Mo) unless otherwise stated. (ϩ/Ϫ)isoproterenol (ISO) and [-]-norepinephrine (NE) were freshly made in H 2 O before each experiment. ICI118,551 (ICI) and carbachol (CCh) stock solutions were prepared in H 2 O. Prazosin (Praz) stock solution was dissolved in methanol. Atenolol and salbutamol (Salb) stock solutions were dissolved in DMSO. All stock solutions were stored at Ϫ20°C. The stock solutions were freshly diluted in bath solution immediately before experimental recording. Ascorbic acid (30 mol/L) was added together with all other drugs in the bath to prevent oxidation of drugs tested. The final concentrations of methanol (0.01%) and DMSO (Ͻ0.1%) have no effect on I Ca,L in control experiments (data not shown).
Pacing-Induced HF and Isolation of Canine Ventricular Myocytes
HF was induced with rapid ventricular pacing at 220 to 250 bpm for 4 to 5 weeks in adult mongrel dogs as previously described. 20 The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23, revised 1996). Dogs were obtained from Twin-Valley Kennel, Spring Green, Wis. Myocytes were isolated from 17 control dogs and 15 failing dogs using enzymatic digestion with collagenase (1 mg/mL, Worthington Type II) plus hyaluronidase (0.5 mg/mL, Sigma Type I-S), as described elsewhere. 21 
␤-AR Radioligand Binding
Membrane fractions highly enriched in sarcolemma were prepared from canine ventricular muscle as previously described 17 and were then used for radioligand binding using [ 125 I]iodocyanopindolol ([ 125 I]CYP; New England Nuclear, Boston, MA), a nonselective high-affinity ␤-AR antagonist using vacuum filtration method with a 24-well harvester (Brandel, Gaithersburg, Md), as described previously. 22 One micromole per liter (-)propranolol was used to determine total and nonspecific binding. Saturation binding data were fit to a single site-binding model, and competition-binding curves were fit to single-or 2-site competition models using nonlinear regression analysis.
Electrophysiological Recordings
Isolated ventricular myocytes were placed in the experimental chamber mounted on the stage of an inverted microscope and studied using the ruptured whole-cell configuration of the patch clamp technique at 22 to 23°C. In a subset of experiments, myocytes were treated for 3 hours with 2 g/mL pertussis toxin (PTX) at 37°C to inactivate G i . 10, 23, 24 Patch pipette solution consisted of (in mmol/L) 90 Cs-glutamate, 20 CsCl, 10 1,2-bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetate, 5 MgATP, and 10 HEPES (pH 7.2). The bath solution to measure L-type Ca 2ϩ channel currents consisted of (in mmol/L) 140 tetraethylammonium-Cl, 1 MgCl 2 , 1.8 CaCl 2 , 10 glucose, and 10 HEPES (pH 7.4). Myocytes were held at a membrane potential of Ϫ80 mV, and 200-ms depolarizations to ϩ20 mV at 10-mV step were applied at 20-s intervals to evaluate the effect of pharmacological interventions on I Ca,L using whole-cell patch clamp techniques, as described previously. 14 
Statistics
All values are presented as meanϮSEM. Statistical significance was evaluated by the paired or unpaired Student's t test (2 tail) or ANOVA followed by Student-Newman-Keuls test when appropriate. Values of PϽ0.05 were considered statistically significant. Microsoft Excel 2000 (Redmond, Wash), WaveMetrics Igor 4.0 (Lake Oswego, Ore), and Microcal Origin 6.0 (Northampton, Mass) were used for data analysis and figure plotting.
Results
Blunted ␤-Adrenergic Stimulation of I Ca,L With ISO in HF
We first used the ruptured whole-cell patch clamp technique to assess the effect of nonselective ␤-AR stimulation (ISO) on I Ca,L in control and tachycardia-induced failing canine ventricular myocytes. Representative current traces as well as the peak I Ca,L are plotted in response to test pulses to ϩ20 mV as a function of time in Figure 1A and 1B, and the effect of serial exposure to increasing concentrations of ISO, was assessed. In control myocytes, I Ca,L is dramatically increased by 332Ϯ35% on superfusion of 0.1 mol/L ISO (nϭ11, PϽ0.001). In contrast, I Ca,L recorded from myocytes of failing dogs showed only a 129Ϯ20% (nϭ7) increase in response to 0.1 mol/L ISO. Testing higher concentrations of ISO (1.0 and 10 mol/L) showed no additional increase in I Ca,L ( Figure  1C ). These results demonstrate that the maximal stimulation of I Ca,L by the nonselective ␤-AR agonist ISO is markedly reduced in HF. This blunted response of I Ca,L to ISO is similar to that observed in patients with HF and earlier studies in animal models. 12, 13, 15 Experiments testing ␤ 2 -AR activation alone using the ␤ 2 -AR agonist Salb (10 mol/L) in the presence of the ␤ 1 -AR He et al ␤ 2 -AR Opposes ␤ 1 -AR Stimulation of I Ca,L in HF antagonist atenolol (1.0 mol/L) revealed no effect on I Ca,L in either control (I Ca,L at 20 mV, basal 5.3Ϯ0.6 pA/pF versus Salbϩatenolol 5.1Ϯ0.6 pA/pF, nϭ3; Pϭnot significant) or failing cells (I Ca,L at 20 mV, basal 4.8Ϯ0.5 pA/pF versus Salbϩatenolol, 4.6Ϯ0.4 pA/pF, nϭ4; Pϭnot significant). A lack of effect of ␤ 2 -AR regulation of basal I Ca,L in normal canine ventricular myocytes has been observed by some investigators, 25 but others have suggested that ␤ 2 -AR activation can increase I Ca,L in normal canine myocytes. 26 Nevertheless, under our conditions, the present results indicate that ␤ 1 -AR signaling is primarily responsible for the increase in I Ca,L observed in response to nonselective ␤-AR stimulation with ISO in both control and failing myocytes.
Downregulation of Surface and T-Tubular Sarcolemma ␤ 1 -AR in HF
Previous studies have determined that ␤ 1 -ARs are downregulated in HF, but it is unknown whether changes in the subcellular distribution of ␤-ARs further contribute to the impaired regulation of I Ca,L in HF. We examined the abundance of ␤ 1 -AR and ␤ 2 -AR in control and failing dogs in membranes enriched in surface sarcolemma (FI) and T-tubular sarcolemma (FII). Equilibrium binding studies revealed that nonselective ␤-AR antagonist [ 125 I]CYP bound with comparable affinities in control and failing hearts with K D values of 0.058Ϯ0.01 and 0.056Ϯ0.02 nmol/L, respectively, for FI membranes, and comparable results were found with FII membranes (see Table I in the online data supplement available at http://circres.ahajournals.org). We determined the relative proportion of ␤ 1 -AR and ␤ 2 -AR by performing competition assays with the ␤ 1 -AR antagonist atenolol and the ␤ 2 -AR antagonist ICI (Figure 2 and online  Table II ). Atenolol, over the concentration range tested, displaced [ 125 I]CYP bound to ␤ 1 -AR and was fit with a single-site displacement curve ( Figure 2A and 2D and online Table II ). In contrast, ICI displaced both a high-affinity component and a low-affinity component correlating with ␤ 2 -AR and ␤ 1 -AR, respectively, and the data were fit to a 2-site displacement curve ( Figure 2B and 2E and online Table  II ). Both competition strategies revealed a significant decrease in the density of ␤ 1 -AR with HF and no significant change in the density of ␤ 2 -AR. Average data for ICI competition are displayed in Figure 2C and 2F and show that ␤ 1 -AR receptors are decreased in both the surface sarcolemma-enriched FI and the T-tubular-enriched FII by 55Ϯ4% (nϭ7, PϽ0.001) and 45Ϯ10% (nϭ7, PϽ0.01), respectively. Furthermore, the results suggest that the ␤ 1 -AR (Figure 3) . ICI alone has no significant effect on I Ca,L in control and failing myocytes, suggesting that there was no significant agonist-free activation of the receptor. In control myocytes, application of 1 mol/L ISO in the continued presence of ICI increased in I Ca,L (352Ϯ26%, nϭ14) to a comparable degree compared with ISO effect in the absence of ICI (332Ϯ33%, nϭ8). However, in failing cells, ICI unmasked a significantly larger stimulatory effect by 1 mol/L ISO on I Ca,L (325Ϯ36%) than without ICI pretreatment (179Ϯ22%, nϭ7, PϽ0.01). These results suggest that specifically in failing, but not control ventricular myocytes, ␤ 2 -AR activation blunts the ␤ 1 -AR stimulation of I Ca,L .
Activation of ␤ 2 -AR Inhibits I Ca,L Stimulated by ␤ 1 -AR Agonist in HF
We performed a complementary experiment examining the regulation of I Ca,L by specific ␤ 1 -AR stimulation using NE with Praz to inhibit ␣ 1 -AR. Then we superfused the ␤ 2 -AR agonist Salb in the continued presence of ␤ 1 -AR stimulation, as shown in Figure 4 . In control canine myocytes, NE (1 mol/L)ϩPraz (1 mol/L) increased I Ca,L 325Ϯ23% (nϭ7) comparable to the effect of ISO on control myocytes (332Ϯ35%, nϭ11). In failing myocytes, NEϩPraz increased I Ca,L to a similar extent as observed in control myocytes (365Ϯ51%, nϭ6). Superfusion of 10 mol/L Salb in the 
He et al ␤ 2 -AR Opposes ␤ 1 -AR Stimulation of I Ca,L in HF
continued presence of NEϩPraz had no effect in control myocytes, but Salb resulted in an inhibition of NEϩPrazstimulated I Ca,L in failing myocytes (183Ϯ25% increase relative to basal, nϭ6, PϽ0.01). These results show that the response of I Ca,L to specific ␤ 1 -AR stimulation is not significantly impaired in this model of HF, but the opposing action of ␤ 2 -AR stimulation blunts the ␤ 1 -AR effect when the receptors are simultaneously activated.
Inhibitory Action of ␤ 2 -AR in HF Requires G i
Because an increased abundance of G i protein has been identified in various models of HF, 9, 27 and because ␤ 2 -AR are known to be capable of coupling with G i , 19, 28 we tested the impact of PTX inactivation of G i on ␤-AR regulation of I Ca,L ( Figure 5 ). First, we demonstrated that PTX pretreatment is effective by testing the ability of CCh, a muscarinic receptor agonist acting via G i , to inhibit ISO-stimulated I Ca,L . Figure  5A and 5B shows that 200 mol/L CCh inhibited ISOstimulated I Ca,L in both control (nϭ3) and failing cells (nϭ6), but these effects were abolished in PTX-treated control (nϭ8) and failing (nϭ7) cells ( Figure 5C and 5D ). Thus, PTX treatment functionally inactivates G i -mediated regulation of I Ca,L in both control and failing myocytes. Inactivation of G i by PTX pretreatment in control myocytes did not alter the effect of 1 mol/L ISO on I Ca,L (compared in Figure 5E ). However, the response of failing cells to 1 mol/L ISO was significantly greater with PTX treatment than without (463Ϯ36%, nϭ7 and 129Ϯ49%, nϭ6; PϽ0.05). These results demonstrate that, specifically in failing myocytes, G i -activated pathways serve to blunt the response of I Ca,L to nonspecific ␤-AR stimulation with ISO, and this suggests that ␤ 2 -AR-mediated inhibition of ␤ 1 -AR stimulation of I Ca,L in failing cells occurs via G i . To test directly whether PTX pretreatment in failing myocytes altered the ␤ 2 -AR-mediated blunting of ␤ 1 -AR stimulation of I Ca,L , we stimulated I Ca,L with NEϩPraz (␤ 1 -AR stimulation) and then added the ␤ 2 -AR agonist Salb ( Figure  6 ). In PTX-pretreated control myocytes, 1 mol/L NEϩ1 mol/L Praz strongly stimulated I Ca,L (374Ϯ31%, nϭ7; Figure 6A and 6C) , and no effect of Salb was observed. These results were similar to that seen in non-PTX-pretreated myocytes (compare to Figure 4 ). PTX effectively inactivated G i in these experiments as CCh did not inhibit the NEϩPrazstimulated I Ca,L . In failing myocytes pretreated with PTX, NEϩPraz stimulated I Ca,L to a similar extent as in control myocytes (383Ϯ62%, nϭ6); however, 10 mol/L Salb failed to inhibit the effect of NEϩPraz on I Ca,L ( Figure 6B ). Thus, inactivation of G i in the failing myocytes prevented ␤ 2 -ARmediated inhibition of ␤ 1 -AR stimulation of I Ca,L .
Discussion
The ability of the nonselective ␤-AR agonist ISO to stimulate I Ca,L in canine HF is markedly reduced, and this is accompanied by a downregulation of specifically ␤ 1 -ARs in both surface and T-tubular membrane fractions. Using ␤-AR subtype-specific agonists and antagonists, we demonstrated that the major part of the blunted response to ISO in failing cells is attributable to ␤ 2 -AR-induced inhibition of the ␤ 1 -AR stimulation of I Ca,L . Studies using PTX have revealed that ␤ 2 -ARs act via G i in failing cells to blunt the ␤ 1 -AR response. This form of crosstalk between ␤ 1 -AR and ␤ 2 -AR was not observed in control myocytes and suggests that, despite an unchanged density of ␤ 2 -AR in failing hearts, there are important alterations in the coupling to downstream signaling molecules. Furthermore, the present results suggest that previous studies of ␤-AR desensitization in HF using nonselective ␤-AR agonists (eg, ISO) could have been complicated by crosstalk between ␤-AR subtypes.
G i -Mediated Crosstalk Between ␤ 2 -AR and ␤ 1 -AR Receptors
The interaction of sympathetic and parasympathetic inputs to precisely regulate cardiac function is an important example of crosstalk between signaling pathways at the whole organ level. The concept of accentuated antagonism was first used by Levy to describe the phenomenon of vagal stimulation reducing heart rate to a greater extent in the presence of elevated sympathetic tone. 29 Studies at the cardiomyocyte level measuring I Ca,L have refined the idea of accentuated antagonism to describe the M 2 -muscarinic-mediated inhibition of I Ca,L , which occurs to a greater extent or is only observed in the presence of ␤-AR stimulation of I Ca,L . 30 The M 2 -muscarinic receptors are coupled via G i or G o to exert this inhibitory effect. 31, 32 Initially, it was proposed that a simple inhibition of AC by G i relative to the G s -mediated AC stimulation explained the competing effects of muscarinic and ␤-AR stimulation on I Ca,L 33 ; however, there are other possible mechanisms including the activation of phosphatases or NO-induced activation of cGMP-dependent phosphodiesterases. 34, 35 The possibility that ␤ 2 -AR stimulation can oppose the ␤ 1 -AR/G s -mediated stimulation of AC has been anticipated since the original observations that the ␤ 2 -AR can variably couple to G s and G i . 19, 28 Opposing effects of ␤ 1 -AR and ␤ 2 -AR stimulation have been described in the regulation of cell survival and apoptosis in the heart. 36, 37 Opposing effects of G s -and G i -coupled ␤ 2 -AR in myocytes on contraction, Ca 2ϩ transients, and I Ca,L have been extensively investigated in rat ventricular myocytes, but the present work describes a new paradigm where ␤ 2 -AR coupled to G i can inhibit ␤ 1 -AR stimulation of I Ca,L , analogous to previously described examples of accentuated antagonism. This finding bares similarity to a recent study using rat ventricular myocytes that specifically, when overexpressing the Na/Ca exchanger, exhibited ␤ 2 -AR/G i -mediated inhibition of ␤ 1 -AR stimulation of contraction. 38 Altered coupling of ␤ 2 -AR with G i in the setting of HF observed in this study is consistent with the increased abundance of G i found in failing human hearts and in this animal model of HF. 9, 11 In addition, agonist-mediated conversion of ␤ 2 -AR from G s coupling to G i coupling may be particularly relevant in the failing heart, where persistent elevations in adrenergic signaling are present. The ability of PTX treatment to partially restore the blunted contractile response to nonspecific ␤-AR stimulation has been observed previously in a rat myocardial infarction HF model and in myocytes from failing human heart. 23, 39 More recently, the role of G i signaling on ␤-AR subtype-specific regulation of contraction was examined in the end-stage SHR rat model of HF, and Xiao et al 10 found evidence for increased G i signaling by ␤ 2 -AR activation, negating the positive inotropic effect of ␤ 2 -AR stimulation in the failing hearts, but the ␤ 2 -AR-G i pathway did not impact the ␤ 1 -AR-positive inotropic effect, in apparent contrast to our results. These apparently conflicting results could be attributable to differences in species studied, HF model, or parameters measured.
Subcellular Localization and Compartmentalization of ␤-AR Signaling
The impact of HF on ␤-AR regulation of I Ca,L may also be affected by changes in subcellular localization of signaling molecules and channels. At the level of the surface sarcolemma and T-tubule sarcolemma, we found that the percentage decrease in ␤ 1 -ARs was comparable in both surface and T-tubular sarcolemma fractions; however, this does not exclude alterations in distribution on a smaller scale. For example, ␤ 2 -ARs are preferentially localized to caveolae in heart cells according to some investigations, and this membrane pool is not resolved by the present membrane fractionation studies. 40 ␤ 2 -AR regulation of AC and downstream L-type Ca 2ϩ channels is highly compartmentalized to the sarcolemma relative to the more diffuse ␤ 1 -AR regulation. 19 Scaffold proteins play a critical role in enabling efficient and localized signaling by bringing the needed molecules in the signaling cascade together. In addition, in rat brain, the ␤ 2 -AR was found to be associated directly with Ca v 1.2 in a macromolecular signaling complex. 18 Therefore, the precise localization and composition of macromolecular signaling complexes could easily be altered in the failing heart. In particular, it is striking that in HF, the typically localized ␤ 2 -AR signaling impacts what has previously been defined as a more diffuse ␤ 1 -AR regulation of I Ca,L .
Clinical Implications and Future Directions
There are potential clinical implications of the present study for human HF, where ␤-AR agonists and antagonists play a prominent role in therapy. For example, short-term inotropic support of failing hearts typically uses relatively selective ␤ 1 -AR agonists such as dobutamine and dopamine rather than the nonselective ␤-AR agonist ISO. This clinical preference has developed based on many factors, but it is possible that a He et al ␤ 2 -AR Opposes ␤ 1 -AR Stimulation of I Ca,L in HF greater efficacy of ␤ 1 -AR stimulation in the absence of ␤ 2 -AR stimulation is partly responsible. The present study does not address the effects of long-term ␤-AR-receptor stimulation or blockade in HF. For example, recent studies have pointed to the potentially beneficial effect of long-term ␤ 2 -ARspecific stimulation in the failing heart in reducing apoptosis and cardiac remodeling. 37, 41 Such long-term effects improving overall contractility with ␤ 2 -AR agonists may seem in conflict with the short-term inhibition ␤ 1 -AR-mediated stimulation of I Ca,L by ␤ 2 -AR signaling in failing myocytes, but a reduction of Ca 2ϩ influx may be beneficial in the long-term for cell survival and, thus, overall cardiac function. Furthermore, alterations in a wide variety of signaling molecules in HF add significant complexity, which makes simple extrapolation of the present results to clinical HF difficult. The downstream signaling pathways from G i responsible for the ␤ 1 -AR and ␤ 2 -AR crosstalk are unknown. Does G i act to directly blunt AC activation or are alternative pathways active, such as the phosphatidylinositol 3-kinase pathway leading to activation of NO synthase-3, important, as suggested by some studies in other cardiac preparations? 24, 42 The role of NO is of particular interest, given accumulating evidence that NO is critically involved in the reduced effect of ␤-AR stimulation in the failing heart. 43 There are many steps in the ␤ 1 -AR regulation of I Ca,L that could potentially be modulated by NO, but future studies will be necessary to evaluate HF-induced alterations in this signaling. Could changes in the colocalization of the critical downstream molecules and ␤-AR be involved? Ultimately, unraveling the complexities of ␤-AR signaling in the failing heart will provide new opportunities to refine therapy.
